Brokers Issue Forecasts for Kinnate Biopharma Inc.’s Q3 2024 Earnings (NASDAQ:KNTE)

Kinnate Biopharma Inc. (NASDAQ:KNTEFree Report) – Leerink Partnrs issued their Q3 2024 EPS estimates for shares of Kinnate Biopharma in a note issued to investors on Monday, February 5th. Leerink Partnrs analyst A. Berens expects that the company will earn ($0.28) per share for the quarter. The consensus estimate for Kinnate Biopharma’s current full-year earnings is ($2.50) per share. Leerink Partnrs also issued estimates for Kinnate Biopharma’s FY2024 earnings at ($1.30) EPS, FY2025 earnings at ($1.16) EPS and FY2026 earnings at ($1.10) EPS.

Separately, Wedbush reiterated a “neutral” rating and set a $2.00 price objective on shares of Kinnate Biopharma in a research report on Wednesday, January 17th. Four equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $12.20.

View Our Latest Stock Report on Kinnate Biopharma

Kinnate Biopharma Price Performance

Shares of KNTE opened at $2.29 on Thursday. The firm has a market capitalization of $107.89 million, a PE ratio of -0.82 and a beta of 1.35. Kinnate Biopharma has a fifty-two week low of $1.04 and a fifty-two week high of $7.41. The company’s 50-day moving average is $2.37 and its 200-day moving average is $2.05.

Kinnate Biopharma (NASDAQ:KNTEGet Free Report) last issued its quarterly earnings data on Thursday, November 9th. The company reported ($0.65) earnings per share for the quarter, beating the consensus estimate of ($0.69) by $0.04.

Institutional Trading of Kinnate Biopharma

Several institutional investors and hedge funds have recently bought and sold shares of the company. Acadian Asset Management LLC raised its holdings in shares of Kinnate Biopharma by 1,389.9% during the 2nd quarter. Acadian Asset Management LLC now owns 430,802 shares of the company’s stock valued at $1,304,000 after buying an additional 401,887 shares in the last quarter. Foresite Capital Management V LLC lifted its stake in Kinnate Biopharma by 78.5% in the second quarter. Foresite Capital Management V LLC now owns 3,525,957 shares of the company’s stock worth $10,684,000 after acquiring an additional 1,550,956 shares during the period. Prelude Capital Management LLC purchased a new stake in Kinnate Biopharma in the second quarter worth about $87,000. Pale Fire Capital SE purchased a new stake in shares of Kinnate Biopharma in the 2nd quarter worth about $72,000. Finally, Creative Planning purchased a new stake in shares of Kinnate Biopharma in the 2nd quarter worth approximately $37,000.

Kinnate Biopharma Company Profile

(Get Free Report)

Kinnate Biopharma Inc, a clinical-stage oncology company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program.

Read More

Earnings History and Estimates for Kinnate Biopharma (NASDAQ:KNTE)

Receive News & Ratings for Kinnate Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kinnate Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.